| Literature DB >> 32621412 |
Wen Zhong1, Yan Lou1, Chenyang Qiu2, Donglin Li2, Hongkun Zhang2.
Abstract
Stenting for iliac vein stenosis or compression has become a common therapeutic approach in recent years. The antithrombotic therapy after the stent deployment, however, reaches no consensus. Medications strategies and patients' prognoses differ in non-thrombotic, acute thrombotic and chronic thrombotic these three circumstances. Non-thrombotic patients usually possess satisfactory stent patency whatever antithrombotic therapy is used. Anticoagulant is the basic medication for acute thrombotic patients, benefits from additional antiplatelet drug remains to be clarified. In terms of chronic thrombotic patients, their prognoses are unsatisfactory under all antithrombotic therapies. In this review, we outlined the recent progress of antithrombotic therapy after iliac vein stenting, aiming to provide feasible medication plans for each circumstance.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32621412 PMCID: PMC8800714 DOI: 10.3785/j.issn.1008-9292.2020.02.15
Source DB: PubMed Journal: Zhejiang Da Xue Xue Bao Yi Xue Ban ISSN: 1008-9292